2-[3-[2-[(25)-2-cyano-1-pyrrolidinyl]-2-oxoethylamino]-3-methyl-1-oxobutyl] -1,2,3,4-tetrahydroisoquinoline: A potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV

Hsu Tsu, Xin Chen, Chiung Tong Chen, Shiow Ju Lee, Chung Nien Chang, Kuo His Kao, Mohane Selvaraj Coumar, Yen Ting Yeh, Chia Hui Chien, Hsin Sheng Wang, Ke Ta Lin, Ying Ying Chang, Ssu Hui Wu, Yuan Shou Chen, I. Lin Lu, Su Ying Wu, Ting Yueh Tsai, Wei Cheng Chen, Hsing Pang Hsieh, Yu Sheng ChaoWeir Torn Jiaang

研究成果: Article同行評審

25 引文 斯高帕斯(Scopus)

摘要

Dipeptidyl peptidase IV (DPP-IV) inhibitors are expected to become a new type of antidiabetic drugs. Most known DPP-IV inhibitors often resemble the dipeptide cleavage products, with a proline mimic at the P1 site. As off-target inhibitions of DPP8 and/or DPP9 have shown profound toxicities in the in vivo studies, it is important to develop selective DPP-IV inhibitors for clinical usage. To achieve this, a new class of 2-[3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2- oxoethyl]amino]-1-oxopropyl]-based DPP-IV inhibitors was synthesized. SAR studies resulted in a number of DPP-IV inhibitors, having IC50 values of <50 nM with excellent selectivity over both DPP8 (IC50 > 100 μM) and DPP-II (IC50 > 30 μM). Compound 21a suppressed the blood glucose elevation after an oral glucose challenge in Wistar rats and also inhibited plasma DPP-IV activity for up to 4 h in BALB/c mice. The results show that compound 21a possesses in vitro and in vivo activities comparable to those of NVP-LAF237 (4), which is in clinical development.

原文English
頁(從 - 到)373-380
頁數8
期刊Journal of Medicinal Chemistry
49
發行號1
DOIs
出版狀態Published - 2006 一月 12

All Science Journal Classification (ASJC) codes

  • 分子醫學
  • 藥物發現

指紋

深入研究「2-[3-[2-[(25)-2-cyano-1-pyrrolidinyl]-2-oxoethylamino]-3-methyl-1-oxobutyl] -1,2,3,4-tetrahydroisoquinoline: A potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV」主題。共同形成了獨特的指紋。

引用此